C12N 2770/36121
Viruses as such
Official title: Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2770/36121 (Viruses as such) appears on 41 US grants and 59 published applications in this corpus.
Search patents in C12N- Granted patents
- 41
- Published applications
- 59
- Assignees
- 42
- Inventors
- 137
- Latest grant
- 3 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 5 | 0 |
| 2003 | 1 | 2 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 1 | 1 |
| 2007 | 0 | 0 |
| 2008 | 1 | 2 |
| 2009 | 0 | 0 |
| 2010 | 1 | 4 |
| 2011 | 0 | 3 |
| 2012 | 0 | 1 |
| 2013 | 2 | 1 |
| 2014 | 3 | 5 |
| 2015 | 1 | 2 |
| 2016 | 3 | 2 |
| 2017 | 4 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 3 |
| 2020 | 1 | 3 |
| 2021 | 1 | 3 |
| 2022 | 3 | 8 |
| 2023 | 3 | 5 |
| 2024 | 2 | 4 |
| 2025 | 3 | 5 |
| 2026 | 2 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-Δ5nsP33 Mar 2026US 12,564,625 B2Valneva SE
- M1 virus mutant and use thereof20 Jan 2026US 12,529,037 B2Guangzhou Virotech Pharmaceutical Co., Ltd.
- Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapy12 Aug 2025US 12,383,589 B2Massachusetts Institute of Technology
- Sindbis control virus24 Jun 2025US 12,338,463 B2LGC Clinical Diagnostics, Inc.
- Methods for in vitro evolution of constructs derived from viruses29 Apr 2025US 12,286,646 B2Massachusetts Institute of Technology
- Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp320 Aug 2026US 2026/0240977 A1Valneva SE
- Modified madariaga viruses, self-replicating rna constructs, and uses thereof30 Jul 2026US 2026/0218170 A1Replicate Bioscience, Inc.
- M1 virus mutant and use thereof7 May 2026US 2026/0125657 A1Guangzhou Virotech Pharmaceutical Co., Ltd.
- Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy5 Mar 2026US 2026/0061013 A1Massachusetts Institute of Technology
- Alphavirus (Mayaro virus) Constructs Attenuated for Human and Method of its Use18 Dec 2025US 2025/0381263 A1Institut Pasteur de Montevideo
Most cited
By later US patents
- cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof74US 5,185,440 ANorth Carolina State University · 1993
- Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis38US 7,811,812 B2Novartis Vaccines and Diagnostics, Inc. · 2010
- Mutated alpha virus35US 5,532,154 AResearch Development Foundation · 1996
- Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis28US 6,391,632 B1Chiron Corporation · 2002
- Alphavirus structural protein expression cassettes26US 6,426,196 B1Chiron Corporation · 2002